ResearcherDuke UniversityActive in the last 2 years
Michael E. Lidsky
Matched on ORCID iD 0000-0003-0500-2016; OpenAlex author ID A5033995118. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper
Papers 6
- Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients. Co-author DOI 10.1245/s10434-025-18232-6↗
- A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. Co-author DOI 10.1007/s00262-025-04146-5↗
- SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Co-author DOI 10.1097/sla.0000000000006966↗
- Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
- Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy. Co-author DOI 10.1245/s10434-023-13318-5↗
- Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Co-author DOI 10.1097/sla.0000000000001924↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dan German Blazer · 5 shared papers, 2017–2026 · strength 0.97
- Paper Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Vete… DOI 10.1245/s10434-025-18232-6↗
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. DOI 10.1186/s12967-025-07381-7↗
- Daniel P. Nussbaum · 5 shared papers, 2017–2026 · strength 0.97
- Paper Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Vete… DOI 10.1245/s10434-025-18232-6↗
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemoth… DOI 10.1245/s10434-023-13318-5↗
- Peter J. Allen · 3 shared papers, 2023–2026 · strength 0.69
- Paper Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Vete… DOI 10.1245/s10434-025-18232-6↗
- Paper Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. DOI 10.1186/s12967-025-07381-7↗
- Paper Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemoth… DOI 10.1245/s10434-023-13318-5↗
- Sabino Zani · 3 shared papers, 2023–2025 · strength 0.59
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. DOI 10.1186/s12967-025-07381-7↗
- Paper Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemoth… DOI 10.1245/s10434-023-13318-5↗
- Elishama N. Kanu · 3 shared papers, 2023–2025 · strength 0.58
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemoth… DOI 10.1245/s10434-023-13318-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Austin M. Eckhoff · 2 shared papers, 2023–2025 · strength 0.39
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemoth… DOI 10.1245/s10434-023-13318-5↗
- Julia Button · 2 shared papers, 2025 · strength 0.39
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Ethan S. Agritelley · 2 shared papers, 2025 · strength 0.39
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Sabran J. Masoud · 1 shared paper, 2026 · strength 0.30
- Allison N. Martin · 1 shared paper, 2026 · strength 0.30
- Vinod P. Balachandran · 1 shared paper, 2025 · strength 0.20
- Mengyuan Liu · 1 shared paper, 2025 · strength 0.20
- Kevin C. Soares · 1 shared paper, 2025 · strength 0.20
- Michael Ian D'Angelica · 1 shared paper, 2025 · strength 0.20
- Tao Wang · 1 shared paper, 2025 · strength 0.20
- Erika J. Crosby · 1 shared paper, 2025 · strength 0.20
- Jeffrey A. Drebin · 1 shared paper, 2025 · strength 0.20
- Diane L. Reidy‐Lagunes · 1 shared paper, 2025 · strength 0.20
- Peter J. Allen · 1 shared paper, 2025 · strength 0.20
- William R. Jarnagin · 1 shared paper, 2025 · strength 0.20
- T. Peter Kingham · 1 shared paper, 2025 · strength 0.20
- Alice Chia-Chi Wei · 1 shared paper, 2025 · strength 0.20
- Alex B. Blair · 1 shared paper, 2025 · strength 0.20
- Erin M. Dickey · 1 shared paper, 2025 · strength 0.19
- David G. Brauer · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.